VolitionRX Ltd (NYSEMKT:VNRX) is set to release its earnings data before the market opens on Friday, November 10th. Analysts expect VolitionRX to post earnings of ($0.15) per share for the quarter.

Separately, HC Wainwright set a $10.00 target price on VolitionRX and gave the stock a “buy” rating in a report on Friday, August 11th.

ILLEGAL ACTIVITY WARNING: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/11/03/volitionrx-ltd-vnrx-scheduled-to-post-earnings-on-friday.html.

VolitionRX Company Profile

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.

Earnings History for VolitionRX (NYSEMKT:VNRX)

Receive News & Ratings for VolitionRX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX Ltd and related companies with MarketBeat.com's FREE daily email newsletter.